Inviragen, Inc. has announced the initiation of a Phase 2, randomized, double-blind, placebo-controlled study of DENVax, the Company’s investigational dengue vaccine. The Phase 2 trial will test the ...
FORT COLLINS, Colo.--(BUSINESS WIRE)--Inviragen, Inc. today announced the initiation of the second stage of an ongoing Phase 2, randomized, double-blind, placebo-controlled study of DENVax™, the ...
Inviragen, Inc., a company focused on developing vaccines to protect against infectious diseases worldwide, has begun the second stage of an ongoing phase II, randomized, double-blind, ...
FORT COLLINS, Colo.--(BUSINESS WIRE)--Inviragen, Inc. today announced the initiation of a Phase 2, randomized, double-blind, placebo-controlled study of DENVax, the Company’s investigational dengue ...
FORT COLLINS, Colo. & MEDELLÍN, Colombia--(BUSINESS WIRE)--Inviragen, a company developing vaccines to protect against infectious diseases worldwide, and the Program for the Study and Control of ...
- Positive Phase 1 Safety and Immunogenicity Results to be Presented at 2011 ASTMH Meeting - FORT COLLINS, Colo.--(BUSINESS WIRE)--Inviragen, Inc. today announced the initiation of a Phase 2, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results